Sign In
Buy LLY
$1,231.58
+45.87 (+3.87%)
At Close: Aug 10, 2026
Eli Lilly Stock Could Reclaim Former Highs
01:04pm, Wednesday, 11'th Jan 2023
According to BMO, near-term hurdles such as competition for key drugs and patent expiries won't derail the long-term revenue and earnings growth of Eli Lilly And Co (NYSE:LLY).
Should You Invest in the iShares U.S. Healthcare ETF (IYH)?
11:20am, Wednesday, 11'th Jan 2023 Zacks Investment Research
Sector ETF report for IYH
Eli Lilly Had a Strong Year in 2022. It's Expecting an Even Better 2023.
10:15am, Wednesday, 11'th Jan 2023
The company has multiple growth catalysts on the horizon that could propel the stock this year and beyond.
Eli Lilly and Company (LLY) 41st Annual J.P. Morgan Healthcare Conference (Transcript)
09:31pm, Tuesday, 10'th Jan 2023
Eli Lilly and Company (NYSE:LLY ) 41st Annual J.P. Morgan Healthcare Conference January 10, 2023 6:45 PM ET Company Participants Anat Ashkenazi - Chief Financial Officer Daniel Skovronsky - Chief Scie
Campbell Soup and Eli Lilly have been highlighted as Zacks Bull and Bear of the Day
01:27pm, Tuesday, 10'th Jan 2023 Zacks Investment Research
Campbell Soup and Eli Lilly have been highlighted as Zacks Bull and Bear of the Day.
Bear of the Day: Eli Lilly (LLY)
11:20am, Tuesday, 10'th Jan 2023 Zacks Investment Research
Guidance for this year drags down analyst EPS estimates by nearly 10% to just 9% growth
Is Alexandria Real Estate Equity a Buy?
10:00am, Tuesday, 10'th Jan 2023 The Motley Fool
It's a great stock, but investors dislike the sector.
Bear of the Day: Eli Lilly (LLY)
07:32am, Tuesday, 10'th Jan 2023
Guidance for this year drags down analyst EPS estimates by nearly 10% to just 9% growth
Ranking The Top 10 Pharmaceuticals By Pipeline
11:44pm, Monday, 09'th Jan 2023
The pipeline is the heart of a drug discovery company. As such, analyzing the health of a pipeline can lead to suggestions about future performance.
Biogen (BIIB), Eisai's Lecanemab Gets FDA Nod for Alzheimer's
03:04pm, Monday, 09'th Jan 2023 Zacks Investment Research
FDA approves Biogen (BIIB) and Eisai's lecanemab on an accelerated basis. Eisai filed a supplemental biologics license application (sBLA) to the FDA to get a traditional approval for Leqembi.
General Motors And These 2 Healthcare Majors On CNBC's 'Final Trades'
01:17pm, Monday, 09'th Jan 2023 Benzinga
On CNBC’s "Halftime Report Final Trades," Bryn Talkington of Requisite Capital Management named Pfizer Inc. (NYSE: PFE), saying that it offers "growth at a reasonable price."
Benzinga's analyst
Dozens in Congress beat stock market in 2022 despite downturn on Wall Street: analysis
06:11pm, Saturday, 07'th Jan 2023 MarketWatch
More than two dozen members of Congress beat the stock market despite Wall Street suffering its worst year since 2008, according to an analysis by a popular stock-trading news site.
3 No-Brainer Dividend Stocks to Buy in 2023
11:10am, Saturday, 07'th Jan 2023 The Motley Fool
These stocks have what it takes to win over the long run.
3 No-Brainer Dividend Stocks to Buy in 2023
06:10am, Saturday, 07'th Jan 2023
These stocks have what it takes to win over the long run.
Eli Lilly (LLY) Gains But Lags Market: What You Should Know
10:45pm, Friday, 06'th Jan 2023 Zacks Investment Research
Eli Lilly (LLY) closed at $362.94 in the latest trading session, marking a +1.12% move from the prior day.
